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Abstract A 37-mer hammerhead ribozyme has been designed to efficiently cleave the 1.4 kb mRNA of the urokinase plasminogen activator eceptor 
(uPAR). Under in vitro conditions, the chemically synthesized ribozyme cleaved uPAR mRNA and inhibited its translation in a concentration- 
dependent fashion. The ribozymes were 5’-[‘5S]thiophosphorylated and used as a model to analyze conditions for RNA delivery in a cultured human 
osteosarcoma cell system. Ribozymes degraded immediately in cell-conditioned medium but ribozymes complexed with lipofectin were protected from 
RNases for up to 22 h. Lipofectin rapidly transported ribozyme into the cell, where it accumulated almost exclusively in the cytoplasm. Thus, hpofectin 
dramatically enhances tability and cytoplasmic delivery of ribozymes, potentially enabling targeting of mRNA in vivo. 
Key words: Hammerhead ribozyme; Delivery; Stability; Urokinase receptor; Lipofectin; HOS cell 
1. Introduction 
The urokinase receptor has been implicated in a series of 
normal and pathological processes of cell migration and inva- 
sion [l]. To evaluate the role of uPAR in such processes, cata- 
lytic RNA molecules targeted to cleave uPAR mRNA would 
be very valuable. 
Experimental results demonstrate that complementary (an- 
tisense) RNA and DNA molecules can be used to interfere with 
the function of targeted RNA molecules (reviewed in [2]). Ri- 
bozymes, a new type of antisense RNA molecule capable of 
cleaving specific target RNAs, have recently been developed 
(reviewed in [3]). The cleavage process is mediated by a precise 
secondary structure formation between the catalytic and sub- 
strate RNA portions. The major advantage in using ribozymes 
is that they can cleave multiple target mRNA molecules, while 
the standard antisense molecules act only in equimolar ratio. 
For in vivo studies, however, utilization of pre-formed ri- 
bozymes is very limited: ribozymes, like other RNA molecules, 
are degraded immediately by RNases present in the culture 
medium. 
Numerous studies have shown that cationic lipids, such as 
lipofectin [4], can effectively deliver RNA [S], DNA [6], or 
protein [7] molecules to mammalian cells in vitro or in vivo. The 
proposed mechanism of action involves lipofectin complex for- 
mation with RNA or DNA, and their subsequent fusion with 
the cell membrane [8]. Lipofectin has been shown to deliver 
pre-formed ribozymes to cells using serum-free culture condi- 
tions [9,10]. 
Here we provide evidence that ribozymes can be effectively 
introduced to cells cultured in serum-supplemented medium. 
Our results demonstrate that lipofectin can stabilize ribozymes 
in cell-conditioned medium presumably by making the ri- 
*Corresponding author. University of Pennsylvania, School of 
Medicine, Cardiovascular Division, 3610 Hamilton Walk, 
Rm 508 Johnson Pavilion, Philadelphia, PA 19104, USA. 
Fax: (1) (215) 662-2947. 
bozyme inaccessible to RNases. We show that ribozymes enter 
the cell very quickly and accumulate in the cytoplasm. 
2. Materials and methods 
Chemically synthesized 37-mer RNA (DNA Synthesis Facility, Wis- 
tar Institute) was 5’-phosphorylated with T4 polynucleotide kinase 
(Promega) to a specific activity of 1.9 CYmmol and 0.6 Ci/mmol using 
[Y-~*P]ATP and [y-“S]ATPS (Amersham) respectively, as described 
[I 11. Target, 5’-capped uPAR mRNA (1370 nt) was synthesized from 
EcoRI (BRL)-linearized pT7TS-uPAR using an SP6 transcriptional 
system (MessageMachine, Ambion). Construction of pT7TSuPAR 
was accomplished by subcloning uPAR coding sequences from pGE- 
MuPAR [12] into pT7TS, which contained 5’ and 3’ untranslated re- 
gions of Xenopus/?-globin mRNA (provided by Dr. P.A. Krieg, Univer- 
sity of Texas, Austin). 
Cleavage was performed by incubating the reaction mixture contain- 
ing 0.05 ,KM mRNA, 1 .O PM ribozyme and 1 mM GTP in RNAzyme 
buffer (USB) at 50°C for 1 h. RNAs were separated on denaturing, 4% 
polyacrylamideiTBE gels, then electro-blotted to Nytran+ membranes 
(Schleicher and Schuell) [I 31. Northern analysis was performed accord- 
ing to standard protocols [14], using hybridization solution (3’Prime- 
5’Prime) and a cDNA probe specific to the 5’ end (nts 51-141) of uPAR 
mRNA (Accession: X51675). To generate this cDNA probe, we used 
a 5’ primer (YGTCACCCGCCGCTGCTG3’) corresponding to nt 51- 
67, a 3’ primer (SCCGTTGGTCTTACACTGCAT3’) corresponding 
to nt 141-122, and template pGEMuPAR [12] in a PCR reaction 
(Perkin-Elmer). The gel-purified 91 bp probe was labeled by random 
priming (Boehringer-Manheim). Signals on the Northern blot were 
quantitated using storage phosphor technology (PhosphorImager, Mo- 
lecular Dynamics). The filters were also exposed to Kodak XAR film 
using an intensifier screen, at -70°C for 6 h. 
uPAR protein synthesis was performed in a coupled transcriptional 
and translational system of rabbit reticulocyte lysate (TNT, Promega) 
using pGEMuPAR [12]. The incubation was performed in the presence 
or absence of ribozymes (0.25-25 PM) or antisense DNA (25 ,uM) for 
90 min in [35S]cysteine-supplemented lysate. Samples were separated by 
10% SDS-PAGE. Fluorograms were generated as described [14]. 
To determine the stability of ribozymes in cells and culture medium, 
human osteosarcoma cells (HOS; ATCC) were seeded into 24-well 
plates (2 x 10’ cells/well) 1 day prior to the experiment. Ribozyme was 
complexed with lipofectin (BRL) in a 2:5 ratio (w/w) by incubating at 
room temperature for 15 min as recommended. The “S-labeled ri- 
bozyme (0.6 PM) or its complex with lipofectin was added to cells and 
incubated at 37°C for 0.5, 2.5 and 22 h in 0.3 ml culture medium 
consisting of DMEM (Gibco) and 10% heat-inactivated fetal bovine 
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serum (Gibco). At the end of incubation, the culture medium was 
collected and cells were harvested. RNA was extracted from cells and 
culture medium (30 ~1) in the presence of 4 pug carrier tRNA (BRL) 
using RNazol (Biotecx) as recommended. After measuring radioactiv- 
ity in aliquots of the aqueous and organic phases by scintillation count- 
ing, the RNA was precipitated, resolved in 80% deionized formamide 
(Clontech) and electrophoresed in a 16% PAGE/TBE gel under non- 
denaturing conditions. The dried gel was exposed to Kodak XAR film 
at -80°C for l-7 days. 
To determine the subcellular localization of “P-labeled ribozymes, 
nuclei and cytoplasm of the treated cells were separated as described 
[15]. Briefly, HOS cells (1 x 106) were cultured in 6-well plates in 1 ml 
of medium under the conditions described above. Cells were treated 
with the lipofectin-complexed ribozyme for 5, 10, 20, 30, 60 and 180 
min, washed with PBS, collected in 0.5 ml trypsin-EDTA, transferred 
to a microtube, then lysed by vortexing in 150@ buffer containing 0.5% 
NP40 in 10 mM Tris-HCI, pH 8.5, 1.5 mM MgCI, and 140 mM NaCI, 
for 2 min at 25°C. The extent of cell lysis was assessed by examining 
an ahquot of the cell lysate by microscopy. Nuclei and cytoplasm were 
separated by centrifuging the lysate at 12,000 rpm in a microfuge. 
RNAs were extracted from the pelleted nuclei, from the supernatant 
cytoplasm, and from an aliquot (30~1) of culture medium with RNazol. 
Samnles were analvzed in a 16% PAGEffBE gel under denaturing 
(8 M urea) conditions. 
Secondary structure predictions for RNAs were generated by the 
MacDNASIS program (Hitachi) using a minimum free energy folding 
algorithm [16]. 
3. Result and discussion 
3.1. Optimizing ribozyme design 
Based on the sequence requirements for hammerhead struc- 
ture formation between target RNA and ribozyme [17], we have 
designed ribozymes targeted to cleave uPAR mRNA. First, we 
analyzed all of the 34 potential ribozyme cleavage sites (GUN, 
where n = G,U,A,C) on the uPAR mRNA. We have selected 
sites on the mRNA that were predicted not to be involved in 
stable structure formation with the neighboring sequences, be- 
cause the secondary structure of the target RNA can inhibit 
assembly of the hammerhead domain [18,19]. As a further eval- 
uation, we predicted secondary structures for all of the 
ribozymes that could be targeted to the selected sites. The 
ribozyme, shown with the complementary sequences of uPAR 
mRNA (nt 124-139) (Accession: X51675), which was one of 
those predicted to fold into the desired secondary structure 
(Fig. l), was chosen for further studies. 
3.2. Cleavage of uPAR mRNA by ribozyme 
The cleavage reaction was performed using 20-fold molar 
excess of the chemically synthesized 37-mer ribozyme over the 
in vitro transcribed 1370 nt uPAR mRNA substrate. The reac- 
tion mixture, separated by denaturing PAGE, was analyzed by 
Northern blot using a radiolabeled probe specific for the 5’ end 
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Fig. I. Predicted secondary structure of the ribozyme with the uPAR 
mRNA template. The cleavage site is indicated by an arrow. 
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Fig. 2. Specific cleavage of uPAR mRNA by ribozyme. The target 1370 
nt uPAR mRNA was incubated with or without ribozyme for 1 h at 
50°C. Samples were separated by denaturing 4% PAGE and transferred 
to a filter. The autoradiogram of the Northern blot, probed with a 
cDNA corresponding to the 5’ end of uPAR mRNA, is shown. The 
positions of the visualized 1370 nt substrate mRNA and the 158 nt 5’ 
cleavage product are indicated. 
of uPAR mRNA. This probe selectively identifies the 5’ cleav- 
age products with the predicted size of 158 nt and the substrate 
mRNA (1370 nt) but can not hybridize to the 3’ cleavage prod- 
uct (1212 nt) (Fig. 2). Phosphor image analysis of the Northern 
blot shown in Fig. 2 demonstrated that 3.9% of the substrate 
uPAR mRNA was specifically cleaved by the ribozyme. This 
result clearly demonstrates that the ribozyme is an enzymati- 
tally functional molecule. The ribozyme activity was also tested 
in rabbit reticulocyte lysates. Using the coupled TNT system, 
we transcribed and translated the uPAR mRNA in the same 
lysate. The TNT system made isolation of the mRNA unneces- 
sary and made it more likely that the mRNA secondary struc- 
ture would stay in its nascent form. Ribozyme specifically in- 
hibited uPAR protein synthesis in a concentration-dependent 
manner (Fig. 3). Synthesis of the-50 kDa and -70 kDa unspec- 
ified proteins from internal mRNAs present in the reticulocyte 
lysates was not inhibited. The conventional antisense oligonu- 
cleotide that was targeted against the identical mRNA se- 
quences was only marginally effective (Fig. 3). These data sug- 
gest that ribozyme might be active under physiologically more 
relevant cell lysate conditions. 
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Fig. 3. Inhibition of uPAR synthesis by ribozyme. Coupled transcrip- 
tion and translation of uPAR was performed in the presence of 
ribozyme or antisense DNA. Samples were incubated in [Z5S]cysteine- 
supplemented rabbit reticulocyte lysates at 37°C for 90 min, then sep- 
arated by 10% SDS-PAGE. The position of the 37 kDa human uPAR 
is indicated on the fluorogram. 
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3.3. Stability of ribozyme in HOS cells and in cell culture 
medium 
To investigate the effect of lipofectin on the stability and 
cellular uptake of the ribozyme, we have introduced the phos- 
phatase-resistant [3SS]thiomonophosphate label [20] to the 
5’ end of the synthetic ribozyme. Considering that RNA is 
degraded predominantly by 3’ exonucleases present in the 
serum and cell supernatants [21], the S-end labeling should not 
increase the ribozyme overall stability. We used non-denaturing 
TBE-PAGE and fluorography to detect ribozyme which was 
recovered from the culture medium and from the treated cells. 
Ribozymes directly added to the culture medium of HOS cells 
were degraded immediately, presumably by RNases present in 
the serum (Fig. 4, lanes l-3). However, ribozymes complexed 
with lipofectin prior to the experiments urvived and were still 
detectable after a 22 h incubation period (Fig. 4, lanes 4-6). 
These results suggest hat lipofectin confers RNase resistance 
to ribozymes in cell culture medium possibly by steric inhibi- 
tion. 
Analysis of RNA isolated from cells that were treated with 
ribozyme alone, as expected, resulted in no detectable amount 
of intact ribozyme (Fig. 4, lanes 7-9). However, ribozyme could 
be recovered from cells that had been treated with the lipo- 
fectin-ribozyme complex (Fig. 4, lanes 10-12). Intact ri- 
bozymes were detectable ven at the end of a 22 h incubation 
period. About l-3% (-2-6 x lO_” mol) of the added 300 ~10.6 
,uM ribozyme could be recovered from HOS cells (2.5 x 10’) 
treated for 0.5 h, suggesting that lipofectin can efficiently trans- 
fer ribozymes to the cells, where the ribozyme accumulates at 
-1-10 x lo6 molecules/cell. 
3.4. Subcellular distribution of the lipofectin delivered ribozyme 
We have previously reported that DNA entrapped in phos- 
pholipid liposomes were successfully delivered into cells in cul- 
ture [22]. The transport was fast (-5-10 min) and about 90% of 
the delivered DNA accumulated in the nuclei within 20 min. To 
evaluate the subcellular localization of the lipofectin-delivered 
ribozymes, we S-end labeled the ribozymes with the more easily 
detectable [32P]monophosphate. Cells treated with ribozyme- 
lipofectin complex were separated to cytoplasmic and nuclear 
fractions after different incubation periods. RNAs isolated 
cuiture medium cells 
lipofectin: - - - + + + - - - + + + 
time [hl: 0.5 2.5 22 0.5 2.5 22 0.5 2.5 22 0.5 2.5 22 
Fig. 4. Ribozyme stability in culture medium and cells. HOS cells were 
incubated with ‘?+labeled ribozyme which was or was not reacted to 
complex with lipofectin. RNAs isolated from the medium and cells were 
separated by non-denaturing 16% PAGE. Position of the intact ri- 
bozyme is indicated on the fluorograms by an arrow. 
incubation time [min]: 5 10 M 30 60 WI 
Fig. 5. Subcellular localization of the lipofectin delivered ribozyme. 
HOS cells were incubated with lipofectin-complexed “P-labeled ri- 
bozyme. RNAs were extracted from the culture medium, and from 
isolated nuclei and cytoplasm. Samples were separated by denaturing 
16% PAGE. The autoradiogram of the dried gel is shown. 
from the cytoplasm, nuclei and culture medium were analyzed. 
The results presented in Fig. 5 demonstrate that ribozyme was 
taken up very quickly by the HOS cells, and the majority of 
intact ribozymes were located in the cytoplasm. After a 22 h 
incubation period, no ribozyme could be detected in any of the 
analyzed fractions (not shown). Presumably, serum and cellular 
enzymes removed the monophosphate labeling, which, unlike 
the 5’ thiomonophosphates, is susceptible to phosphatases [20]. 
These data suggest he superiority of 35S over 32P for labeling 
the 5’ end of the pre-formed ribozymes that are planned for use 
in cellular studies. Reports have already suggested that lipo- 
fectin-complexed molecules are preferentially transported to 
the cytoplasm [23], while others proposed nuclear localization 
of the delivered products [9]. One possible explanation for the 
discrepancies could be the different methods for isolation of the 
nuclear fraction. To achieve a better separation of the subcellu- 
lar fractions we used a more stringent nuclei isolation proce- 
dure, which was specifically recommended for extranuclear 
RNA analysis [15]. 
In summary, these studies suggest hat positions 124-139 of 
the 1.4 kb uPAR mRNA are accessible for ribozyme-mediated 
cleavage. Our data indicate that lipofectin, in addition to assist- 
ing ribozyme delivery to cells, also protects the ribozyme from 
degradation by serum nucleases. These results suggest hat pre- 
formed ribozyme delivered with lipofectin may be useful in the 
analysis of the role of uPAR in different biological processes. 
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